FDA Seeks Public Feedback on Regulatory Approaches for Generative AI-Enabled Medical Devices
The U.S. Food and Drug Administration has released a discussion paper outlining potential regulatory approaches for **generative AI-enabled medical devices**, covering risk assessment, premarket evaluation, and postmarket monitoring. The agency is seeking early stakeholder input to help shape future policy frameworks for clinical AI, with comments due by October 19, 2026.
About LOG Standards
LOG Standards provides an independent accreditation signal for AI models used in healthcare, helping hospitals, care networks, and AI companies bring clinical AI readiness and governance into clearer conversations.
Our AI Intelligence Briefing tracks the latest developments in AI safety, AI in medicine, mental health AI, clinical AI governance, and regulatory policy — keeping healthcare stakeholders informed about the rapidly evolving AI landscape.